GIC-002

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameGIC-002
Drug Alias Name靶向HPV16-E6/E7抗原自体免疫T细胞注射液GIC002GIC-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenoimmune Therapeutics
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGenoimmune Therapeutics
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A